vman1300
Never Forgotten
I know most folks dont spend their time looking at cancer research unless they are affected or know someone that is.....but lookie what I found tonight about a new drug called TroVax.
"Phase I/II Trial
Colorectal cancer "“ TroVax as a single agent post chemotherapy
22 patients with Stage IV metastatic colorectal cancer
TroVax induced an anti-tumour immune response in 94 % of patients.
41 % of patients showed periods of disease stabilisation
The immune response induced by TroVax correlated with time to disease progression (p < 0.01) and a relationship was determined with survival
Phase II Trials (two trials)
Colorectal cancer "“ TroVax alongside first line chemotherapy with FOLFOX or IFL
36 patients with Stage IV metastatic colorectal cancer
TroVax induced an anti-tumour immune response in all patients
95 % of patients showed disease stabilisation
17 % of patients showed complete tumour responses
In the TroVax plus FOLFOX trial, the immune response induced by TroVax correlated with tumour responses (p < 0.02)
25 % of patients were alive at an average follow-up time of almost two and a half years
of course, even with FDA fast track, this is still 2 to 3 years out, but still exciting, particularly if the stage II trials hold up the same response - I can live with 95% stablization
"Phase I/II Trial
Colorectal cancer "“ TroVax as a single agent post chemotherapy
22 patients with Stage IV metastatic colorectal cancer
TroVax induced an anti-tumour immune response in 94 % of patients.
41 % of patients showed periods of disease stabilisation
The immune response induced by TroVax correlated with time to disease progression (p < 0.01) and a relationship was determined with survival
Phase II Trials (two trials)
Colorectal cancer "“ TroVax alongside first line chemotherapy with FOLFOX or IFL
36 patients with Stage IV metastatic colorectal cancer
TroVax induced an anti-tumour immune response in all patients
95 % of patients showed disease stabilisation
17 % of patients showed complete tumour responses
In the TroVax plus FOLFOX trial, the immune response induced by TroVax correlated with tumour responses (p < 0.02)
25 % of patients were alive at an average follow-up time of almost two and a half years
of course, even with FDA fast track, this is still 2 to 3 years out, but still exciting, particularly if the stage II trials hold up the same response - I can live with 95% stablization